Trial Profile
Use of Ixmyelocel-T (Formerly TRC Autologous Bone Marrow Cells) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2016
Price :
$35
*
At a glance
- Drugs Ixmyelocel-T (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral arterial disorders
- Focus Adverse reactions
- Acronyms RESTORE-CLI
- Sponsors Aastrom Biosciences; Vericel Corporation
- 31 Oct 2014 New trial record